0001193805-24-000323.txt : 20240306 0001193805-24-000323.hdr.sgml : 20240306 20240306215141 ACCESSION NUMBER: 0001193805-24-000323 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240304 FILED AS OF DATE: 20240306 DATE AS OF CHANGE: 20240306 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PHILLIPS BARCLAY A CENTRAL INDEX KEY: 0001265801 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36201 FILM NUMBER: 24727982 MAIL ADDRESS: STREET 1: C/O CANCER VAX CORP STREET 2: 2110 RUTHERFORD ROAD CITY: CARLSBAD STATE: CA ZIP: 92008 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNIC, INC. CENTRAL INDEX KEY: 0001280776 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 562358443 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1200 AVENUE OF THE AMERICAS STREET 2: SUITE 200 CITY: NEW YORK STATE: X1 ZIP: 10036 BUSINESS PHONE: (332) 255-9818 MAIL ADDRESS: STREET 1: 1200 AVENUE OF THE AMERICAS STREET 2: SUITE 200 CITY: NEW YORK STATE: X1 ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: VITAL THERAPIES INC DATE OF NAME CHANGE: 20040219 4 1 e619337_4-phillips.xml X0508 4 2024-03-04 0 0001280776 IMMUNIC, INC. IMUX 0001265801 PHILLIPS BARCLAY A 1200 AVENUE OF THE AMERICAS, SUITE 200 NEW YORK NY 10036 1 0 0 0 0 Stock Option 7.63 2024-03-04 4 D 0 19973 D 2029-11-14 Common Stock 29959 0 D Stock Option 7.63 2024-03-04 4 D 0 9986 D 2029-11-14 Common Stock 9986 0 D Stock Option 12.3 2024-03-04 4 D 0 15000 D 2030-07-02 Common Stock 15000 0 D Stock Option 14.77 2024-03-04 4 D 0 10000 D 2031-06-10 Common Stock 10000 0 D Stock Option 3.4 2024-03-04 4 D 0 10000 D 2032-06-15 Common Stock 10000 0 D Stock Option 1.72 2024-03-04 4 A 0 64959 A Common Stock 64959 64959 D On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date. /s/ Barclay Phillips 2024-03-06